Jpmorgan Chase & CO Ovid Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,463,838 shares of OVID stock, worth $1.55 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,463,838
Previous 1,466,433
0.18%
Holding current value
$1.55 Million
Previous $1.13 Million
52.97%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding OVID
# of Institutions
75Shares Held
39MCall Options Held
37.4KPut Options Held
500-
Rubric Capital Management LP New York, NY5.32MShares$5.63 Million0.17% of portfolio
-
Madison Avenue Partners, LP New York, NY4.12MShares$4.36 Million0.6% of portfolio
-
Black Rock Inc. New York, NY3.99MShares$4.23 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.85MShares$4.09 Million0.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.14MShares$3.33 Million0.0% of portfolio
About Ovid Therapeutics Inc.
- Ticker OVID
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,419,400
- Market Cap $74.6M
- Description
- Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...